CHI Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

CHI Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-837	Closed	-$4K	–	29
2022 Q2	$4K	Buy	+837	New	+$169K	﹤0.01%	28

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CHI Advisors's EIGR Position: Q4 2022 in Review

CHI Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 15,170 shares — an estimated $3.43M sold.

CHI Advisors first reported a position in EIGR in Q2 2022 and held it in 2 quarters. The position peaked at $3.43M in Q3 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

CHI Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
CHI Advisors sold 15,170 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $3.43M.
CHI Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2022 and held it in 2 quarters.
CHI Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $3.43M in Q3 2022.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on CHI Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.